samedan logo
 
 
 
spacer
home > ebr > spring 2017 > balancing act
PUBLICATIONS
European Biopharmaceutical Review

Balancing Act

Escherichia coli has been the historical workhorse for the production of therapeutic proteins since the first biologic, insulin, hit the market in 1982. It continues to be a preferred system, because operations are inexpensive and timelines are short. Pharmaceutical companies tune the fermentation procedure for the greatest yield in every batch by maximising the cell density per batch and per cell expression. Peak cell density is obtained through process optimisation, and maximal specific productivity is achieved by strain/vector engineering.

These two activities require different research skillsets and are often performed independently of each other. Small virtual companies with preclinical programmes often separate these activities by outsourcing them to different firms. One service provider develops a strain, which is then transferred to a contract manufacturing organisation to maximise the cell density in order to enable the isolation of sufficient product to file an investigational new drug and support Phase 1 and 2 trials.

Such strategies often rely on the assumption that fine-tuning the process can occur during early clinical development. The downfall, however, occurs when fermentation cannot be significantly improved without genetic engineering of the strain. Creation of an entirely new master cell bank constitutes a major procedure change that means going ‘back to the drawing board’. If the end goal is to hand the therapeutic to a large pharma company in order to launch a commercial process, then this downfall can represent a considerable decrease in value.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
April Stanley is the Manager of Cell Line and Strain Development at Cytovance, and earned her Master’s Degree from the University of Illinois, US, in Microbiology. During her six years at Cytovance, she has designed the company’s E. coli toolbox and currently leads the team that developed the platform fermentation processes, which match the production strains generated with the toolbox.
spacer
April Stanley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement